Skip to main content
. Author manuscript; available in PMC: 2014 Sep 23.
Published in final edited form as: Autoimmunity. 2010 Aug 9;44(2):137–148. doi: 10.3109/08916934.2010.482116

Figure 6.

Figure 6

AdLeptin protects syngeneic islet grafts in diabetic recipients. BBDR rats induced to become diabetic following pIC+KRV treatment were given AdLeptin or AdBetagal and transplanted with syngeneic islets as described in Methods. A. Diabetes free survival following transplantation of syngeneic islets. Data presented are pooled from two independent experiments; AdLeptin vs. AdBetagal (p=0.01). Median diabetes free survival time was 26 days in the islet engrafted AdBetagal group and > 50 days in the AdLeptin group. B. AdLeptin protected islet grafts are surrounded by lymphocytic infiltrates but maintained positive insulin and glucagon staining. Representative islet graft from an AdLeptin treated, non-diabetic rat was identified under the kidney capsule. C. AdLeptin treated rats that remained normoglycemic following islet transplantation had their graft-bearing kidney removed to confirm reversion to hyperglycemia. Pancreata were recovered and processed for immunohistochemistry. Serial sections in B and C were stained with H&E, insulin, and glucagon; all images are at 10x magnification.